Valganciclovir
Valganciclovir. L-valyl ester prodrug of ganciclovir — first-pass valine hydrolysis improves oral F to ~60%. Same anti-CMV mechanism. Standard… Oral half-life 3.7 h.
L-valyl ester prodrug of ganciclovir — first-pass valine hydrolysis improves oral F to ~60%. Same anti-CMV mechanism. Standard outpatient CMV prophylaxis post-transplant.
PK: F 0.59 is verbatim and stands, RELABELLED — it measures ganciclovir appearing in plasma after oral valganciclovir, not the prodrug itself, and the two records molecular weights differ by a factor of 1.39, so molar work must name which species it means. Half-life corrected 4 -> 3.73 h from the same ten lung-transplant recipients. V 31.9 L and ka 0.895 /h come from Caldes 2009 (PMID:19738014) in solid-organ transplant patients; the volume is a two-compartment CENTRAL volume being carried in a one-compartment slot, and that paper own bioavailability is 0.825 rather than 0.59, so the mixture of sources is deliberate and recorded. THE ABSORPTION RATE IS ONE OF ONLY TWO GENUINE PUBLISHED HUMAN ka VALUES FOUND IN THE ENTIRE AUDIT of 70 routes. The ganciclovir record oral row was the same measurement double-filed and has been corrected separately. MASS: the stored molecular weight described the PARENT while pk_analyte declares the metabolite, so the one field that must name a single species named the wrong one. LATENT RATHER THAN LIVE — this record carries no occupancy rows and is no other record interaction perpetrator — but it is one authored edge away from being live, because both consumers of the field (the micromolar-to-mass conversion for a kinetics edge, and the affinity the app renders from a stored occupancy concentration) want the species that actually circulates, which is the species pk[] already describes.
Pharmacokinetics
- Oral — t½ 3.7 h · F 59% · ka 0.895 h⁻¹ · Vd 31.9 L
Sources: PMID:22305377, PMID:19738014